Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Human Papillomavirus 16 E6 Antibodies in Individuals Without Diagnosed Cancer: A Pooled Analysis.

Lang Kuhs, Krystle A ; Anantharaman, Devasena ; Waterboer, Tim ; Johansson, Mattias ; Brennan, Paul ; Michel, Angelika ; Willhauck-Fleckenstein, Martina ; Purdue, Mark P ; Holcatova, Ivana and Ahrens, Wolfgang , et al. (2015) In Cancer Epidemiology Biomarkers & Prevention 24(4). p.683-689
Abstract
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having i) moderate (mean fluorescent intensity [MFI]≥484 & <1000) or ii) high seroreactivity (MFI≥1000). Associations of moderate and high HPV16 E6 seroreactivity with i) demographic risk factors;... (More)
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having i) moderate (mean fluorescent intensity [MFI]≥484 & <1000) or ii) high seroreactivity (MFI≥1000). Associations of moderate and high HPV16 E6 seroreactivity with i) demographic risk factors; and seropositivity for ii) other HPV16 proteins (E1, E2, E4, E7 and L1) and iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45 and 52) were evaluated. Results: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking (odds ratio [OR] 5.5 [95% confidence interval [CI]:1.2-51.8]), and seropositivity against HPV16 L1 (OR 4.8, 95%CI:1.3-15.4); E2 (OR 7.7, 95%CI:1.4-29.1); multiple HPV16 proteins (OR 25.3, 95%CI:2.6-119.6 for 3 HPV16 proteins beside E6) and HPV33 E6 (OR 17.7, 95%CI:1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Epidemiology Biomarkers & Prevention
volume
24
issue
4
pages
683 - 689
publisher
American Association for Cancer Research
external identifiers
  • pmid:25623733
  • wos:000351955900006
  • scopus:84925848405
  • pmid:25623733
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-14-1217
language
English
LU publication?
yes
id
acb57ee1-ae14-420b-95cd-a1697eb76c73 (old id 5039611)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25623733?dopt=Abstract
date added to LUP
2016-04-01 11:10:59
date last changed
2022-02-03 00:26:54
@article{acb57ee1-ae14-420b-95cd-a1697eb76c73,
  abstract     = {{Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having i) moderate (mean fluorescent intensity [MFI]≥484 &amp; &lt;1000) or ii) high seroreactivity (MFI≥1000). Associations of moderate and high HPV16 E6 seroreactivity with i) demographic risk factors; and seropositivity for ii) other HPV16 proteins (E1, E2, E4, E7 and L1) and iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45 and 52) were evaluated. Results: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking (odds ratio [OR] 5.5 [95% confidence interval [CI]:1.2-51.8]), and seropositivity against HPV16 L1 (OR 4.8, 95%CI:1.3-15.4); E2 (OR 7.7, 95%CI:1.4-29.1); multiple HPV16 proteins (OR 25.3, 95%CI:2.6-119.6 for 3 HPV16 proteins beside E6) and HPV33 E6 (OR 17.7, 95%CI:1.9-81.8). No associations were observed with moderate HPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection.}},
  author       = {{Lang Kuhs, Krystle A and Anantharaman, Devasena and Waterboer, Tim and Johansson, Mattias and Brennan, Paul and Michel, Angelika and Willhauck-Fleckenstein, Martina and Purdue, Mark P and Holcatova, Ivana and Ahrens, Wolfgang and Lagiou, Pagona and Polesel, Jerry and Simonato, Lorenzo and Merletti, Franco and Healy, Claire M and Kjaerheim, Kristina and Conway, David I and Macfarlane, Tatiana V and Thomson, Peter and Castellsague, Xavier and Znaor, Ariana and Black, Amanda and Huang, Wen-Yi and Krogh, Vittorio and Trichopoulou, Antonia and Bueno-de-Mesquita, H Bas and Clavel-Chapelon, Francoise and Weiderpass, Elisabete and Ekström, Johanna and Riboli, Elio and Tjonneland, Anne and Sanchez, Maria-Jose and Travis, Ruth C and Hildesheim, Allan and Pawlita, Michael and Kreimer, Aimee R}},
  issn         = {{1538-7755}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{683--689}},
  publisher    = {{American Association for Cancer Research}},
  series       = {{Cancer Epidemiology Biomarkers & Prevention}},
  title        = {{Human Papillomavirus 16 E6 Antibodies in Individuals Without Diagnosed Cancer: A Pooled Analysis.}},
  url          = {{http://dx.doi.org/10.1158/1055-9965.EPI-14-1217}},
  doi          = {{10.1158/1055-9965.EPI-14-1217}},
  volume       = {{24}},
  year         = {{2015}},
}